Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 86.38B |
| Revenue (ttm) | 40.94B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.53 |
| PE Ratio | 16.78 |
| Forward PE | 7.75 |
| Dividend | 2.22 (5.25%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 878 |
| Average Volume | 4,073 |
| Open | 42.72 |
| Previous Close | 42.51 |
| Day's Range | 42.34 - 42.76 |
| 52-Week Range | 36.60 - 58.79 |
| Beta | 0.31 |
| RSI | 61.45 |
| Earnings Date | Feb 5, 2026 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers (BMY) Sees Stock Surge on Positive Drug Trial News
Bristol Myers (BMY) Sees Stock Surge on Positive Drug Trial News
Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.
Validea Detailed Fundamental Analysis - BMY
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
BMY Quantitative Stock Analysis
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA (NASDAQ: SNY) and Bristol-Myers Squibb Co (NYSE: BMY) of conceali...
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Bristol-Myers Squibb (BMY) Faces Legal Action Over Plavix Effectiveness Claims
Bristol-Myers Squibb (BMY) Faces Legal Action Over Plavix Effectiveness Claims
Pharma giant gave Irish employee three months to come up with €20,800 to cover alleged ‘overpayment’, WRC hears
Employee challenging legality of Bristol Myers Squibb decision to deduct her salary by €870 a month over two years
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Bristol-Myers Squibb (BMY) Announces Early Results and Amendments to Cash Tender Offers
Bristol-Myers Squibb (BMY) Announces Early Results and Amendments to Cash Tender Offers
Why Bristol-Myers Squibb Remains Undervalued In 2025
Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the early participation results, as of 5:00 p.m. (New York City time) on November 17, 2025, (the “Early Tender Deadli...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2239083912-66ca5844484d4a63ade26baffd7e7760.jpg)
S&P 500 Gains and Losses Today: DoorDash Drives Higher on a New Partnership; Bristol-Myers Squibb Stock Falls
A delivery company got a boost from a new partnership announcement on Friday, Nov. 14, 2025, while the termination of a clinical trial weighed on a pharmaceutical firm.
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy
Bristol Myers Squibb & Co. (NYSE: BMY), in collaboration with Johnson & Johnson (NYSE: JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and saf...
Bristol Myers Slumps After Its Heart Condition Study Gets The Boot
Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.
Bristol Myers Squibb, J&J Discontinue Phase 3 Librexia ACS Study Of Milvexian After Interim Review
(RTTNews) - Bristol-Myers Squibb Co. (BMY) on Friday said it has halted the Phase 3 Librexia ACS trial of milvexian, conducted in partnership with Johnson & Johnson (JNJ), in patients who recently exp...
Bristol Myers (BMY) Shares Drop as Milvexian Trial Faces Setback
Bristol Myers (BMY) Shares Drop as Milvexian Trial Faces Setback
Bristol Myers falls after late-stage trial setback for J&J-partnered blood thinner
Bristol Myers Squibb (BMY) stock drops as the company fails in a key Phase 3 trial for milvexian, an anticoagulant it is advancing with J&J (JNJ). Read more here.
Bristol Myers (BMY) Drops Following Phase 3 Trial Halt
Bristol Myers (BMY) Drops Following Phase 3 Trial Halt
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Interesting BMY Put And Call Options For January 2026
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the...
Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squibb (NYSE: BMY), a leading biopharma...
Evotec (EVO) Secures $5M Milestone from Bristol Myers Squibb
Evotec (EVO) Secures $5M Milestone from Bristol Myers Squibb